Cargando…

Dose–Response Association of Metformin with Parkinson’s Disease Odds in Type 2 Diabetes Mellitus

Background. Studies have demonstrated that patients with diabetes mellitus who receive metformin have a lower risk of developing Parkinson’s disease (PD). However, studies have also suggested that metformin may increase the risk of PD. In this study, we investigated whether metformin use was associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Kuang-Hua, Chang, Ya-Lan, Gau, Shuo-Yan, Tsai, Tung-Han, Lee, Chien-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147745/
https://www.ncbi.nlm.nih.gov/pubmed/35631532
http://dx.doi.org/10.3390/pharmaceutics14050946
_version_ 1784716883197427712
author Huang, Kuang-Hua
Chang, Ya-Lan
Gau, Shuo-Yan
Tsai, Tung-Han
Lee, Chien-Ying
author_facet Huang, Kuang-Hua
Chang, Ya-Lan
Gau, Shuo-Yan
Tsai, Tung-Han
Lee, Chien-Ying
author_sort Huang, Kuang-Hua
collection PubMed
description Background. Studies have demonstrated that patients with diabetes mellitus who receive metformin have a lower risk of developing Parkinson’s disease (PD). However, studies have also suggested that metformin may increase the risk of PD. In this study, we investigated whether metformin use was associated with the risk of PD in type 2 diabetes mellitus (T2DM). Methods. In this population-based cross-sectional study, patients with T2DM diagnosed between 2001 and 2018 were enrolled. We categorized these patients as metformin users or nonusers. Participants below 50 years old were excluded. Two models were employed to evaluate the associations of metformin exposure and use intensity with PD after 3 and 5 years of follow-up. Results. Patients with T2DM who received <300 cumulative defined daily doses (cDDD) of metformin and those with metformin use intensity of <10 DDD/month had respective odds ratios (ORs) for PD of 0.88 (95% confidence interval [CI] = 0.83–0.94) and 0.87 (95% CI = 0.81–0.93) in a 3-year follow-up. In a 5-year follow-up, such patients had respective ORs for PD of 0.94 (95% CI = 0.90–0.98) and 0.93 (95% CI = 0.89–0.98). Patients with T2DM who received ≥300 cDDD of metformin or used metformin with intensity of ≥10 DDD/month experienced no neuroprotective effects after 3 or 5 years. Conclusions. Metformin was associated with PD odds in T2DM in a dose–response association manner. Patients who received low dosage and intensity of metformin use were associated with lower odds of PD, while higher dosage and intensity of metformin use had no neuroprotective effect.
format Online
Article
Text
id pubmed-9147745
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91477452022-05-29 Dose–Response Association of Metformin with Parkinson’s Disease Odds in Type 2 Diabetes Mellitus Huang, Kuang-Hua Chang, Ya-Lan Gau, Shuo-Yan Tsai, Tung-Han Lee, Chien-Ying Pharmaceutics Article Background. Studies have demonstrated that patients with diabetes mellitus who receive metformin have a lower risk of developing Parkinson’s disease (PD). However, studies have also suggested that metformin may increase the risk of PD. In this study, we investigated whether metformin use was associated with the risk of PD in type 2 diabetes mellitus (T2DM). Methods. In this population-based cross-sectional study, patients with T2DM diagnosed between 2001 and 2018 were enrolled. We categorized these patients as metformin users or nonusers. Participants below 50 years old were excluded. Two models were employed to evaluate the associations of metformin exposure and use intensity with PD after 3 and 5 years of follow-up. Results. Patients with T2DM who received <300 cumulative defined daily doses (cDDD) of metformin and those with metformin use intensity of <10 DDD/month had respective odds ratios (ORs) for PD of 0.88 (95% confidence interval [CI] = 0.83–0.94) and 0.87 (95% CI = 0.81–0.93) in a 3-year follow-up. In a 5-year follow-up, such patients had respective ORs for PD of 0.94 (95% CI = 0.90–0.98) and 0.93 (95% CI = 0.89–0.98). Patients with T2DM who received ≥300 cDDD of metformin or used metformin with intensity of ≥10 DDD/month experienced no neuroprotective effects after 3 or 5 years. Conclusions. Metformin was associated with PD odds in T2DM in a dose–response association manner. Patients who received low dosage and intensity of metformin use were associated with lower odds of PD, while higher dosage and intensity of metformin use had no neuroprotective effect. MDPI 2022-04-27 /pmc/articles/PMC9147745/ /pubmed/35631532 http://dx.doi.org/10.3390/pharmaceutics14050946 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Huang, Kuang-Hua
Chang, Ya-Lan
Gau, Shuo-Yan
Tsai, Tung-Han
Lee, Chien-Ying
Dose–Response Association of Metformin with Parkinson’s Disease Odds in Type 2 Diabetes Mellitus
title Dose–Response Association of Metformin with Parkinson’s Disease Odds in Type 2 Diabetes Mellitus
title_full Dose–Response Association of Metformin with Parkinson’s Disease Odds in Type 2 Diabetes Mellitus
title_fullStr Dose–Response Association of Metformin with Parkinson’s Disease Odds in Type 2 Diabetes Mellitus
title_full_unstemmed Dose–Response Association of Metformin with Parkinson’s Disease Odds in Type 2 Diabetes Mellitus
title_short Dose–Response Association of Metformin with Parkinson’s Disease Odds in Type 2 Diabetes Mellitus
title_sort dose–response association of metformin with parkinson’s disease odds in type 2 diabetes mellitus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147745/
https://www.ncbi.nlm.nih.gov/pubmed/35631532
http://dx.doi.org/10.3390/pharmaceutics14050946
work_keys_str_mv AT huangkuanghua doseresponseassociationofmetforminwithparkinsonsdiseaseoddsintype2diabetesmellitus
AT changyalan doseresponseassociationofmetforminwithparkinsonsdiseaseoddsintype2diabetesmellitus
AT gaushuoyan doseresponseassociationofmetforminwithparkinsonsdiseaseoddsintype2diabetesmellitus
AT tsaitunghan doseresponseassociationofmetforminwithparkinsonsdiseaseoddsintype2diabetesmellitus
AT leechienying doseresponseassociationofmetforminwithparkinsonsdiseaseoddsintype2diabetesmellitus